Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Autor: Roloff GW; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Aldoss I; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Kopmar NE; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Dekker SE; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Gupta VK; Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA., O'Connor TE; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Jeyakumar N; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Muhsen IN; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Valtis Y; Memorial Sloan Kettering Cancer Center, New York, NY., Ahmed N; Memorial Sloan Kettering Cancer Center, New York, NY., Zhang A; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Miller K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Dykes KC; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Ahmed M; Cedars-Sinai Medical Center, Los Angeles, CA., Chen EC; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Mercadal S; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Schwartz M; University of Colorado Anschutz School of Medicine, Aurora, CO., Tracy SI; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Mukherjee A; University of Arkansas Medical Center, Little Rock, AK., Battiwalla M; Sarah Cannon Transplant and Cell Therapy Network, Nashville, TN., Logan AC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA., Ladha A; Department of Hematology, Norris Cancer Center, University of Southern California, Los Angeles, CA., Guzowski C; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Hoeg RT; Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA., Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ., Moore J; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Connor MP; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX., Tsai SB; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Sasine JP; Cedars-Sinai Medical Center, Los Angeles, CA., Solh MM; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Kota VK; Georgia Cancer Center, Augusta University, Augusta, GA., Koura D; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Veeraputhiran M; University of Arkansas Medical Center, Little Rock, AK., Leonard JT; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Frey NV; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Park JH; Memorial Sloan Kettering Cancer Center, New York, NY., Luskin MR; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Galal A; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Pullarkat V; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Stock W; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Shah BD; Moffitt Cancer Center, Tampa, FL., Faramand R; Moffitt Cancer Center, Tampa, FL., Muffly L; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 17, pp. JCO2400321. Date of Electronic Publication: 2024 Oct 17.

Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation.

Autor: Solomon SR; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia. Electronic address: ssolomon@bmtga.com., Bachier-Rodriguez L; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Bashey A; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Zhang X; School of Public Health, University of Texas, Houston, Texas., Jackson KC; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Holland HK; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Morris LE; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Solh MM; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Sep; Vol. 30 (9), pp. 903.e1-903.e9. Date of Electronic Publication: 2024 Jun 13.

Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant.

Autor: Solomon SR; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia. Electronic address: ssolomon@bmtga.com., Aubrey MT; Univerisity of Colorado Cord Blood Bank & Clinimmune Lab, Aurora, Colorado., Bachier-Rodriguez L; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Solh MM; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Jackson KC; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Zhang X; School of Public Health, University of Texas, Houston, Texas., Roark CL; Univerisity of Colorado Cord Blood Bank & Clinimmune Lab, Aurora, Colorado., Holland HK; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Morris LE; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Bashey A; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Jun; Vol. 30 (6), pp. 608.e1-608.e10. Date of Electronic Publication: 2024 Mar 30.

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.

Autor: Tamari R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., McLornan DP; Department of Medicine, University College Hospital, London, United Kingdom., Ahn KW; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Estrada-Merly N; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Hernández-Boluda JC; Department of Hematology, Hospital Clínico Universitario, Valencia, Spain., Giralt S; Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Palmer J; Department of Medicine, Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, AZ., Gale RP; Department of Immunology and Inflammation, Haematology Centre, Imperial College London, London, United Kingdom., DeFilipp Z; Department of Medicine, Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA., Marks DI; Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom., van der Poel M; Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Verdonck LF; Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands., Battiwalla M; Outcomes Research, Sarah Cannon Blood Cancer Network, Nashville, TN., Diaz MA; Department of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain., Gupta V; Department of Internal Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada., Ali H; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Litzow MR; Division of Hematology and Transplant Center, Mayo Clinic, Rochester, MN., Lazarus HM; Department of Hematology and Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH., Gergis U; Division of Hematological Malignancies, Department of Medicine Oncology, Thomas Jefferson University, Philadelphia, PA., Bashey A; Department of Medicine, Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA., Liesveld J; Department of Medicine, University of Rochester Medical Center, Rochester, NY., Hashmi S; Department of Internal Medicine, Mayo Clinic, Rochester, MN.; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates., Pu JJ; Department of Medicine, Banner University Medical Center Tucson, Syracuse, NY., Beitinjaneh A; Divison of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL., Bredeson C; Department of Medicine, The Ottawa Hospital Transplant & Cellular Therapy Program, Ottawa, ON, Canada., Rizzieri D; Novant Health Cancer Institute, Winston Salem, NC., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Abid MB; Divisions of Hematology/Oncology & Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Ganguly S; Department of Medicine, Houston Methodist Hospital and Cancer Center, Houston, TX., Agrawal V; Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Ulrike Bacher V; Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Wirk B; Department of Medicine, Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA., Jain T; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Cutler C; Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA., Aljurf M; Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia., Kindwall-Keller T; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA., Kharfan-Dabaja MA; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL., Hildebrandt GC; Division of Hematology, Markey Cancer Center, University of Kentucky, Lexington, KY., Pawarode A; Division of Hematology/Oncology, Department of Internal Medicine, Blood and Marrow Transplantation Program, University of Michigan Medical School, Ann Arbor, MI., Solh MM; The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA., Yared JA; Division of Hematology/Oncology, Department of Medicine, Transplantation & Cellular Therapy Program, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Nathan S; Department of Internal Medicine, Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL., Nishihori T; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Scott BL; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Nakamura R; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Oran B; Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX., Czerw T; Department of Haematology and BMT, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Yakoub-Agha I; Department of Hematology, CHRU Hopital Claude Huriez, Lille, France., Saber W; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.

Publikováno v: Blood advances [Blood Adv] 2023 Aug 08; Vol. 7 (15), pp. 3993-4002.

Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD).

Autor: Solh MM; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA. msolh@bmtga.com., Farnham C; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA., Solomon SR; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA., Bashey A; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA., Morris LE; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA., Holland HK; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA., Zhang X; Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2023 Feb; Vol. 58 (2), pp. 168-174. Date of Electronic Publication: 2022 Nov 09.